Kyntra BIO Executive Compensation (FY25)
FGEN · Executive and director compensation, fiscal 2024 to 2025
Chief executive, fiscal 2025 ◇ Thane Wettig | Latest say-on-pay support = June 12, 2026 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Kyntra BIO brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (8-K): June 16, 2026
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
133 figures on this page: 123 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Thane Wettig: $2,642,113 → $2,113,842 (20.0% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Kyntra BIO's chief executive and what were they paid?
Total compensation for Thane Wettig, Chief Executive Officer and Director, came to $2,113,842 in fiscal 2025. Compared with the $2,642,113 reported for fiscal 2024, Wettig's total was 20.0% lower.
What was Kyntra BIO's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.3% of votes cast including abstentions in favor at the meeting held June 12, 2026.
Which companies are in Kyntra BIO's peer group?
The disclosed peer group includes Actinium Pharmaceuticals, Bolt Therapeutics, Celularity, Chimerix and CytomX Therapeutics, among others. Companies named in the 2025 Compensation Peer Group include ALX Oncology Holdings, Mersana Therapeutics, PDS Biotechnology, PMV Pharmaceuticals and Werewolf Therapeutics, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Thane Wettig Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Deyaa Adib Former Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Christine Chung Senior Vice President, China Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Juan Graham Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
David DeLucia Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Thane Wettig Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christine Chung former Senior Vice President, China Operations Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
David DeLucia Chief Financial Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| David DeLucia | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Thane Wettig | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Thane Wettig | Option | ◇ | — | ◇ | 1/8/2035 |
| Option | ◇ | — | ◇ | 2/20/2034 | |
| Option | ◇ | — | ◇ | 8/6/2033 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/14/2032 | |
| David DeLucia | Option | ◇ | — | ◇ | 1/8/2035 |
| Option | ◇ | — | ◇ | 8/29/2033 | |
| Option | ◇ | — | ◇ | 2/21/2034 | |
| Option | ◇ | — | ◇ | 6/3/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
James A. Schoeneck Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey L. Edwards | ◇ | — | ◇ | — | — | — | ◇ |
Maykin Ho | ◇ | — | ◇ | — | — | — | ◇ |
Michael Kauffman | ◇ | — | ◇ | — | — | — | ◇ |
Aoife Brennan | ◇ | — | — | — | — | — | ◇ |
Thane Wettig served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Stock ownership guideline: Due to the Company effecting a reverse stock split in June 2025, we have currently paused the stock ownership guidelines for directors and officers.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Actinium Pharmaceuticals ATNM
- Bolt Therapeutics BOLT
- Celularity CELU
- Chimerix CMRX
- CytomX Therapeutics CTMX
- Eagle Pharmaceuticals EGRX
- HOOKIPA Pharma HOOK
- Precision BioSciences DTIL
- Protara Therapeutics TARA
- Rallybio RLYB
- RAPT Therapeutics RAPT
- SAB Biotherapeutics SABS
2025 Compensation Peer Group
- ALX Oncology Holdings ALXO
- Mersana Therapeutics MRSN
- PDS Biotechnology PDSB
- PMV Pharmaceuticals PMVP
- Werewolf Therapeutics HOWL
- Whitehawk Therapeutics WHWK
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 12, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 16, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 26, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 4, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 5, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | June 5, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | June 7, 2017 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Thane Wettig (Chief Executive Officer and Director), FY2025 total compensation $2,113,842 (base salary $665,000) [exec_comp, SEC accession 0001193125-26-182044, filed 2026-04-27]What this page does not include
Everything above is a fact Kyntra BIO disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kyntra BIO sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
133 figures on this page: 123 cited to the filing that reported them, 10 calculated from figures it prints.
123 cited to the filing
10 calculated from the filing
Documents cited
- 0001193125-26-271449Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-182044DIRECTOR COMPENSATION · Named Executive Officer
- 0000950170-25-083676Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-25-058841
- 0000950170-24-070636Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-027252Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-22-011825Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-030428Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-20-028777Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-166285Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-18-185611Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-198743
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kyntra BIO executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/FGEN (accessed 2026).
Short form: data: Velarion
The Kyntra BIO brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kyntra BIO and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Kyntra BIO discloses
The companies named in FGEN's own disclosed peer group.
Actinium PharmaceuticalsBolt TherapeuticsCelularityChimerixCytomX TherapeuticsEagle PharmaceuticalsHOOKIPA PharmaPrecision BioSciencesProtara TherapeuticsRallybioRAPT TherapeuticsSAB BiotherapeuticsALX Oncology HoldingsMersana TherapeuticsPDS BiotechnologyPMV PharmaceuticalsWerewolf TherapeuticsWhitehawk Therapeutics
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}